Project Summary:

The main goal of the Medicinal Chemistry Core is to provide a drug discovery engine that will enable each project’s pursuit of small molecule antibacetrials. Often supplying complimentary skills to the project team, the MCC’s staff consists of highly experienced pharmaceutical industry and academic chemists. They are engaged in the iterative cycles of drug discovery and chemical probe evolution to deliver high-quality small molecules with target efficacy, Absorption-Distribution-Metabolism-Excretion, pharmacokinetics, and toxicity profiles.

PI Name:

Joel S. Freundlich


Dr. Freundlich is an associate professor of Pharmacology & Physiology and Medicine at Rutgers University–New Jersey Medical School. He is a faculty member of the Center for Emerging and Reemerging Pathogens. Prior to his return to academic research in 2006, he spent eight years in the pharmaceutical industry as a medicinal chemist. His undergraduate and master’s degree training were in chemical engineering at Cornell University as a McMullen Dean’s Scholar. He received his doctorate in organic chemistry from the Massachusetts Institute of Technology under the tutelage of 2005 Nobel Prize in Chemistry awardee Richard Schrock. An overarching goal of his current research is the discovery of small molecules that modulate novel biological targets in Mycobacetrium tuberculosis – the causative agent of tuberculosis. To accomplish their aims, his lab typically employs computational, chemical, and biological techniques. His laboratory is funded by the National Institutes of Health.

Contact info:

Joel S. Freundlich, Ph.D.
Associate Professor
Departments of Pharmacology & Physiology and Medicine
Center for Emerging and Reemerging Pathogens
Rutgers University
Medical Sciences Building I-503
185 South Orange Avenue
Newark, NJ 07103
(973) 972-7165 (office)